Abstract
In a multicentre, randomized, double-blind controlled trial comparing the low-molecular-weight heparin enoxaparin (40 mg) with a standard unfractionated heparin (Ca-heparin, 3 x 5,000 U) in deep-vein thrombosis prophylaxis in a high-risk group of 959 hospitalized medical patients, enoxaparin was at least as efficacious as standard heparin, with fewer adverse events.
Publication types
-
Clinical Trial
-
Multicenter Study
-
Randomized Controlled Trial
MeSH terms
-
Aged
-
Double-Blind Method
-
Enoxaparin / adverse effects
-
Enoxaparin / therapeutic use*
-
Female
-
Fibrinolytic Agents / adverse effects
-
Fibrinolytic Agents / therapeutic use*
-
Humans
-
Internal Medicine / methods*
-
Male
-
Middle Aged
-
Risk Factors
-
Thrombophlebitis / epidemiology*
-
Thrombophlebitis / prevention & control
Substances
-
Enoxaparin
-
Fibrinolytic Agents